On the day, 674159 shares were traded.
Ratios:
To gain a deeper understanding of VTYX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.87 and its Current Ratio is at 11.87. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on March 12, 2024, Upgraded its rating to Overweight and sets its target price to $16 from $7 previously.
On March 12, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $12.
Wells Fargo Downgraded its Overweight to Equal Weight on November 07, 2023, whereas the target price for the stock was revised from $77 to $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 02 ’24 when Mohan Raju sold 4,312 shares for $5.40 per share. The transaction valued at 23,299 led to the insider holds 1,578,250 shares of the business.
Krueger Christopher W sold 1,651 shares of VTYX for $8,921 on Apr 02 ’24. The CHIEF BUSINESS OFFICER now owns 284,999 shares after completing the transaction at $5.40 per share. On Apr 02 ’24, another insider, Nuss John, who serves as the CHIEF SCIENTIFIC OFFICER of the company, sold 1,651 shares for $5.40 each. As a result, the insider received 8,921 and left with 264,998 shares of the company.
Stock Price History:
Over the past 52 weeks, VTYX has reached a high of $40.58, while it has fallen to a 52-week low of $1.87.
Shares Statistics:
A total of 59.24M shares are outstanding, with a floating share count of 47.09M. Insiders hold about 20.53% of the company’s shares, while institutions hold 89.16% stake in the company.
Earnings Estimates
As of right now, Treasury Yield 30 Years analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $12.02, with high estimates of $4.60 and low estimates of $7.86.
Analysts are recommending an EPS of between $Healthcare and $Technology for the fiscal current year, implying an average EPS of $Technology. EPS for the following year is $Stocks, with Index analysts recommending between $Stocks and $Stocks.
